L363 – Ipracell https://www.ipracell.be Production & exploitation of mammalian cells Thu, 08 Jan 2026 12:15:45 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.4 https://www.ipracell.be/wp-content/uploads/2025/02/cropped-Favicon-32x32.png L363 – Ipracell https://www.ipracell.be 32 32 L363 Cell Pellets https://www.ipracell.be/product/l363-cell-pellets/ Thu, 13 Apr 2017 12:14:56 +0000 http://new.ipracell.be/?post_type=product&p=148 L363 cell
Human plasma cell leukemia established from the peripheral blood of a 36-year-old woman with plasma cell leukemia (IgG) in 1977; cells were described to be EBNA-negative and to express mRNA for proto-oncogene bcl-2 confirmed as human with IEF of AST, LDH, PEP B.

L363 cells Production
L363 cells are grown in sonoperfused fedbatch (cytostat) mode at a constant concentration of 5×106 cells/ml (cell viability: 93%-99%) under GLP conditions in our facility in Mons, Belgium. Cells are harvested in exponential phase.

Cell pellets are prepared by low speed centrifugation, rinsed with phosphate buffer saline, snap frozen in liquid nitrogen and stored at -85°C.

The cell pellets are not prepared in aseptic conditions and are not intended to be used as seed for a new culture.

Research Use Only
Our L363 cell pellets are used by research or production entities worldwide for the study of biochemical processing, high throughput screening or purification of biological material from human origin. For published papers reporting the use of our extract, please check out our references list

Quality Control
Cultures are screened for the presence of bacteries, yeast, fungi and mycoplasma (DNA amplification). Sera used in the culture medium are CE certified from South American origin.

]]>